On May 8, 2024, London-based Compass Pathways, a mental health biotech developing psilocybin treatments, will release Q1 financial results and updates.
London-based biotech Compass Pathways, focused on mental health, will release Q1 financial results and updates on May 8, 2024. The company, developing psilocybin treatments, has a phase 3 program for treatment-resistant depression, and phase 2 studies for PTSD and anorexia nervosa. COMP360 psilocybin treatment, a Breakthrough Therapy by FDA, received Innovative Licensing and Access Pathway in the UK.
May 03, 2024
3 Articles